Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial
- Author(s)
- Fasching, PA; Slamon, D; Nowecki, Z; Kukielka-Budny, B; Stroyakovskiy, D; Yardley, DA; Huang, CS; Chan, A; Chia, S; Martín, M; Rugo, HS; Loi, S; Hurvitz, S; Untch, M; Afenjar, K; Fresco, R; Danyliv, A; Ferrusi, I; Li, Z; Hortobagyi, G;
- Journal Title
- Clinical Cancer Research
- Publication Type
- Online publication before print
- Abstract
- PURPOSE: The phase 3 NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC). Here we report health-related quality of life (HRQOL) data from NATALEE. PATIENTS AND METHODS: Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores (EORTC QLQ-C30 global health status and physical, social, and emotional functioning domains; EORTC QLQ-BR23 breast-symptoms scale; health on a visual analog scale of EQ-5D-5L; and the Hospital Anxiety and Depression Scale) were assessed. The prespecified primary HRQOL endpoint was physical functioning. Mean scores and time-categorical and prespecified linear-time repeated-measure models were used to evaluate HRQOL changes during treatment. RESULTS: HRQOL was evaluated in all patients in the ribociclib plus NSAI (n = 2549) and NSAI alone (n = 2552) arms. Compliance was high in both arms (≈93%-97%). Mean scores did not differ meaningfully from baseline for any analyzed domain. Likewise, neither a meaningful change from baseline (in either treatment arm) nor a difference between arms was observed during treatment in the time-categorical, model-adjusted mean scores for any HRQOL domains-using published thresholds for interpreting longitudinal and between-group differences, with all values being within 0.5 SD of their baseline values. Linear-time regression analysis confirmed these findings. CONCLUSIONS: These analyses of NATALEE show that adding adjuvant ribociclib to an NSAI does not negatively impact HRQOL in patients with HR+/HER2- EBC.
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1158/1078-0432.Ccr-24-1724
- Open Access at Publisher's Site
https://doi.org/10.1158/1078-0432.Ccr-24-1724- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-03-18 06:23:40
Last Modified: 2025-03-18 06:24:11